Current and Future Preparative Regimens for Bone Marrow Transplantation in Thalassemia<sup>a</sup>
R Storb(Fred Hutch Cancer Center), Mark C. Walters(UCSF Benioff Children's Hospital), John L. Wagner(Leipzig University), Keith M. Sullivan(Duke Medical Center), Hans‐Peter Kiem(Fred Hutch Cancer Center), Richard A. Nash(Colorado Blood Cancer Institute), BRENDA M. SANDMAIER(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter A. McSweeney(Mesoblast (United States)), H. Joachim Deeg(Fred Hutch Cancer Center), CONG YU(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), George E. Georges(Northwestern University)
Cited by 37
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k